{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:30:20Z","timestamp":1789421420879,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.thromres.2011.09.011","type":"journal-article","created":{"date-parts":[[2011,10,15]],"date-time":"2011-10-15T12:08:22Z","timestamp":1318680502000},"page":"720-724","source":"Crossref","is-referenced-by-count":7,"title":["Inferior vena cava thrombosis and its relationship with the JAK2V617F mutation and chronic myeloproliferative disease"],"prefix":"10.1016","volume":"129","author":[{"given":"Birgit","family":"Linnemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Roskos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Zgouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelgard","family":"Lindhoff-Last","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.thromres.2011.09.011_bb0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2008.07258.x","article-title":"The JAK2V617F mutation and thrombosis","volume":"143","author":"Austin","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.thromres.2011.09.011_bb0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"issue":"9501","key":"10.1016\/j.thromres.2011.09.011_bb0015","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.thromres.2011.09.011_bb0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.thromres.2011.09.011_bb0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F JAK2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.thromres.2011.09.011_bb0030","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.thromres.2011.09.011_bb0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.thromres.2008.01.004","article-title":"Etiology and VTE risk factor distribution in patients with inferior vena cava thrombosis","volume":"123","author":"Linnemann","year":"2008","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.thromres.2011.09.011_bb0040","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythaemia vera, essential thrombcythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2011.09.011_bb0045","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","article-title":"Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"109","author":"Kr\u00f6ger","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2011.09.011_bb0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.thromres.2011.09.011_bb0055","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1538-7836.2007.02384.x","article-title":"JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis","volume":"5","author":"Regina","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.thromres.2011.09.011_bb0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4065\/83.4.457","article-title":"JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients","volume":"83","author":"Pardanani","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.thromres.2011.09.011_bb0165","article-title":"Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg","author":"Lauw","year":"2011","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.thromres.2011.09.011_bb0170","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.5858\/2006-130-1126-PV","article-title":"Polycythemia vera. New clinicopathologic perspectives","volume":"130","author":"Cao","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.thromres.2011.09.011_bb0075","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMra035363","article-title":"Thrombocytosis","volume":"350","author":"Schafer","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.thromres.2011.09.011_bb0175","first-page":"1712","article-title":"Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome","volume":"91","author":"Smalberg","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.thromres.2011.09.011_bb0085","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jjcc.2008.12.010","article-title":"Thrombo-occlusion of inferior vena cava filter in a patient with polycythemia vera","volume":"54","author":"Muranishi","year":"2009","journal-title":"J Cardiol"},{"issue":"1","key":"10.1016\/j.thromres.2011.09.011_bb0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2000.01817.x","article-title":"Features of essential thrombocythaemia in childhood: a study of five children","volume":"108","author":"Randi","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.thromres.2011.09.011_bb0095","first-page":"477","article-title":"Budd-Chiari syndrome secondary to thrombosis of the inferior vena cava in myeloproliferative disease","volume":"79","author":"Foresti","year":"1998","journal-title":"Minerva Med"},{"issue":"2","key":"10.1016\/j.thromres.2011.09.011_bb0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1751-553X.2010.01275.x","article-title":"JAK2V617F mutation in patients with thrombosis: to screen or not to screen?","volume":"33","author":"Xavier","year":"2010","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.thromres.2011.09.011_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00062752-200701000-00009","article-title":"JAK-2 mutations and their relevance to myeloproliferative disease","volume":"14","author":"Levine","year":"2007","journal-title":"Curr Opin Hematol"},{"issue":"4Pt2","key":"10.1016\/j.thromres.2011.09.011_bb0180","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-2006-942759","article-title":"The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia","volume":"32","author":"Bellucci","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.thromres.2011.09.011_bb0185","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu\/BCAM","volume":"110","author":"Wautier","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2011.09.011_bb0120","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1538-7836.2007.02626.x","article-title":"Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V617F status, clonality, and antiphospholipid antibodies","volume":"5","author":"Robertson","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.thromres.2011.09.011_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3324\/haematol.10358","article-title":"The V617F mutation of JAK2 is very uncommon in patients with thrombosis","volume":"92","author":"Remacha","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.thromres.2011.09.011_bb0130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jmg.2006.048371","article-title":"Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings","volume":"44","author":"Colaizzo","year":"2007","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.thromres.2011.09.011_bb0190","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1538-7836.2007.02811.x","article-title":"EDITH Collaborative Study Group. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism","volume":"6","author":"Ugo","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.thromres.2011.09.011_bb0140","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","article-title":"Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia","volume":"107","author":"Schafer","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2011.09.011_bb0145","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1365-2036.2010.04299.x","article-title":"The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis","volume":"31","author":"Orr","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.thromres.2011.09.011_bb0195","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1582-4934.2009.00747.x","article-title":"Cellular\/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix","volume":"13","author":"Willems","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"8","key":"10.1016\/j.thromres.2011.09.011_bb0155","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.thromres.2011.09.011_bb0160","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","article-title":"JAK2(V617F): prevalence in a large Chinese hospital population","volume":"109","author":"Xu","year":"2007","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384811004981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384811004981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T03:28:40Z","timestamp":1639193320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384811004981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0049384811004981"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2011.09.011","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}